Entity

Time filter

Source Type

Vienna, Austria

Yamada A.,Tokyo Medical University | Kahn L.H.,Princeton University | Monath T.P.,Hookipa Biotech | Conti L.,Consumer Services
Confronting Emerging Zoonoses: The One Health Paradigm | Year: 2014

This book provides readers with information on the factors underlying the emergence of infectious diseases originating in animals and spreading to people. The One Health concept recognizes the important links between human, animal, and environmental health and provides an important strategy in epidemic mitigation and prevention. The essential premise of the One Health concept is to break down the silos among the different health professions and promote transdisciplinary collaborations. These concepts are illustrated with in-depth analyses of specific zoonotic agents and with examples of the successes and challenges associated with implementing One Health. The book also highlights some of the challenges societies face in confronting several specific zoonotic diseases. A chapter is included on comparative medicine to demonstrate the broad scope of the One Health concept. Edited by a team including the One Health Initiative pro bono members, the book is dedicated to those studying zoonotic diseases and comparative medicine in both human and veterinary medicine, to those involved in the prevention and control of zoonotic infections and to those in the general public interested in the visionary field of One Health. © 2014 Springer Japan. All rights reserved. Source


Monath T.P.,Hookipa Biotech | Monath T.P.,Paxvax, Inc. | Vasconcelos P.F.C.,Instituto Evandro Chagas | Vasconcelos P.F.C.,National Institute of Science and Technology for Viral Hemorrhagic Fevers | Vasconcelos P.F.C.,Para State University
Journal of Clinical Virology | Year: 2015

Yellow fever, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of yellow fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of yellow fever, with an emphasis on recent changes in the distribution and incidence of the disease. Recent knowledge about yellow fever 17D vaccine mechanism of action and safety are discussed. © 2014 Elsevier B.V. Source


Trademark
Hookipa Biotech | Date: 2012-09-14

Pharmaceutical and veterinary preparations, in particular preparations for active and passive immunisation, in particular vaccines, such as for infectious disease, cancer and autoimmune disease. Treatment of materials, in particular for the manufacture of preparations for active and passive immunisation, in particular for vaccines, such as for infectious disease, cancer and autoimmune disease. Scientific and technological services related to active and passive immunisation, in particular vaccines, such as for infectious disease, cancer and autoimmune disease, namely, scientific research, pharmaceutical research and development, pharmaceutical testing, analysis, and evaluation, and industrial research related thereto.


Hookipa Biotech | Entity website

Hookipa Biotech AG / Helmut-Qualtinger-Gasse 2 / 1030 Vienna / Austria


Monath T.P.,Kleiner Perkins Caufield & Byers | Monath T.P.,Paxvax, Inc. | Monath T.P.,Hookipa Biotech | Seligman S.J.,New York Medical College | And 9 more authors.
Vaccine | Year: 2015

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viruses inserted into the backbone of another virus (so-called "chimeric virus vaccines"). Many viral vector vaccines are in advanced clinical trials. The first such vaccine to be approved for marketing (to date in Australia, Thailand, Malaysia, and the Philippines) is a vaccine against the flavivirus, Japanese encephalitis (JE), which employs a licensed vaccine (yellow fever 17D) as a vector. In this vaccine, two envelope proteins (prM-E) of YF 17D virus were exchanged for the corresponding genes of JE virus, with additional attenuating mutations incorporated into the JE gene inserts. Similar vaccines have been constructed by inserting prM-E genes of dengue and West Nile into YF 17D virus and are in late stage clinical studies. The dengue vaccine is, however, more complex in that it requires a mixture of four live vectors each expressing one of the four dengue serotypes. This vaccine has been evaluated in multiple clinical trials. No significant safety concerns have been found. The Phase 3 trials met their endpoints in terms of overall reduction of confirmed dengue fever, and, most importantly a significant reduction in severe dengue and hospitalization due to dengue. However, based on results that have been published so far, efficacy in preventing serotype 2 infection is less than that for the other three serotypes. In the development of these chimeric vaccines, an important series of comparative studies of safety and efficacy were made using the parental YF 17D vaccine virus as a benchmark. In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in comparison to the parental YF 17D vaccine. The template facilitates scientific discourse among key stakeholders by increasing the transparency and comparability of information. The Brighton Collaboration V3SWG template may also be useful as a guide to the evaluation of other recombinant viral vector vaccines. © 2014. Source

Discover hidden collaborations